Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

Bo Huang, Ping‐Ying Pan, Qingsheng Li, Alice I. Sato, David E. Levy, Jonathan S. Bromberg, Celia M. Divino, Shu‐Hsia Chen

Cancer Research · 2006 · 1.4K citations · 43 references

Concepts

TL;DR

Accumulation of myeloid suppressor cells (MSCs) in tumor‑bearing mice and cancer patients is linked to immune suppression, with their activity correlating with expression of Gr‑1, CD115, and F4/80 markers. Treg development requires antigen‑associated activation of tumor‑specific T cells, depends on IFN‑γ and IL‑10, and occurs independently of nitric‑oxide–mediated MSC suppression. Gr‑1+CD115+ MSCs suppress T‑cell proliferation, induce anergic Foxp3+ T regulatory cells in vivo, and enhance IL‑10 and TGF‑β secretion upon IFN‑γ stimulation, demonstrating a novel MSC‑mediated immune‑suppressive pathway. Cancer Res 2006; 66(2):1123‑31.

Abstract

Abstract The accumulation of myeloid suppressor cells (MSCs) is associated with immune suppression in tumor-bearing mice and in cancer patients. The suppressive activity of MSC correlates with the expression of the myeloid markers Gr-1, CD115 (macrophage colony-stimulating factor receptor), and F4/80. Gr-1+CD115+ MSCs, in addition to being able to suppress T-cell proliferation in vitro, can induce the development of Foxp3+ T regulatory cells (Treg) in vivo, which are anergic and suppressive. Furthermore, the secretion of interleukin (IL)-10 and transforming growth factor-β by Gr-1+CD115+ MSCs was induced and enhanced, respectively, on IFN-γ stimulation. The development of Treg requires antigen-associated activation of tumor-specific T cells, depends on the presence of IFN-γ and IL-10, and is independent of the nitric oxide–mediated suppressive mechanism by MSC. Our data provide evidence that Gr-1+CD115+ MSC can mediate the development of Treg in tumor-bearing mice and show a novel immune suppressive mechanism by which MSCs can suppress antitumor responses. (Cancer Res 2006; 66(2): 1123-31)

References

43